在创立长达18年后，法国健康科技企业Withings终于实现盈利。这一里程碑式的消息由专注于未来经济报道的媒体Maddyness首发。
18年后，Withings 实现盈利
18 ans plus tard, Withings devient rentable
摘要
Withings 在成立 18 年后首次实现盈利，标志着这家法国健康科技公司在经历被诺基亚收购又回购的波折后，终于达成财务转折点。此次盈利得益于其聚焦预防性健康产品的战略，并验证了其向混合订阅模式转型的成效，为未来的增长奠定了基础。
Withings 在成立 18 年后首次实现盈利，标志着这家法国健康科技公司在经历被诺基亚收购又回购的波折后，终于达成财务转折点。此次盈利得益于其聚焦预防性健康产品的战略，并验证了其向混合订阅模式转型的成效，为未来的增长奠定了基础。
Withings, the French connected health device specialist founded in 2008 by Éric Carreel and Cédric Hutchings, has reached profitability for the first time in its 18-year history. The milestone, disclosed in its 2024 financial results, marks a long-awaited vindication for a company that survived a turbulent acquisition by Nokia in 2016 and a management buyback just two years later.
The firm reported full-year revenue of €100 million, a 47% jump compared to €68 million in 2023, and posted a net profit of €1.5 million. CEO Éric Carreel said in a statement: “This achievement demonstrates that our model—combining consumer-grade design with medical-grade accuracy and a recurring services layer—can be economically viable without sacrificing long-term R&D bets.” R&D spending remains high at roughly 30% of revenue, reflecting the company’s focus on clinical validation for its products.
Withings’ revival has been built on a series of critically acclaimed devices. The Body Scan connected scale, which measures segmental body composition, nerve activity, and cardiovascular health, has been a strong seller since its launch. The ScanWatch 2, a hybrid smartwatch with temperature tracking and sleep apnea detection, and the U-Scan, a urine analysis pod that sits in a toilet bowl, have bolstered the premium health-monitoring lineup. A subscription service, Withings+, provides in-depth health reports and coaching, contributing to a growing share of recurring revenue.
The path to profitability was anything but smooth. After early success with its first connected scale in 2009, Withings was bought by Nokia in 2016 for €170 million, only to see its innovation pace stall under the Finnish giant. Carreel repurchased the assets in 2018 for a fraction of the price, leading a restructuring that refocused the company on medical-grade consumer devices. The COVID-19 pandemic delayed some product launches, but the following years saw a steady climb in sales as health awareness surged.
Looking ahead, Carreel aims to expand Withings’ footprint in the United States and Asia, where partnerships with healthcare providers are budding. The company also plans to deepen its ecosystem of devices and services, leveraging artificial intelligence to turn raw biometric data into actionable health insights. While profitability is modest, the achievement signals that Withings has finally found a sustainable formula at the intersection of consumer tech and regulated health data.
Résumé
Withings, la société française spécialisée dans la santé connectée, annonce être devenue rentable après 18 ans d'existence, marquant une étape clé dans son développement et démontrant la viabilité économique de son modèle dans la tech.
Withings, la société française spécialisée dans la santé connectée, annonce être devenue rentable après 18 ans d'existence, marquant une étape clé dans son développement et démontrant la viabilité économique de son modèle dans la tech.
L’article 18 ans plus tard, Withings devient rentable est apparu en premier sur Maddyness - Le média pour comprendre l'économie de demain.
Core Point
Withings, the French connected health device maker, has reached profitability after 18 years, signaling a long-gestation maturation in the niche health hardware market.
Key Players
- Withings — Consumer electronics company specializing in smart scales, watches, and health monitors, based in Issy-les-Moulineaux, France.
Industry Impact
- Terminals/Consumer Electronics: Medium — Validates demand and business model for dedicated health devices.
Tracking
[Monitor] — Profitability milestone after prolonged investment may indicate a tipping point for connected health hardware; worth following expansion and competitive moves.